Prophylactic implantable cardioverter defibrillator therapy in high-risk patients with coronary artery disease

dc.contributor.authorKolettis, T. M.en
dc.contributor.authorSaksena, S.en
dc.date.accessioned2015-11-24T18:56:02Z
dc.date.available2015-11-24T18:56:02Z
dc.identifier.issn0002-8703-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18973
dc.rightsDefault Licence-
dc.subjectAdrenergic beta-Antagonists/therapeutic useen
dc.subjectAnti-Arrhythmia Agents/therapeutic useen
dc.subjectArrhythmias, Cardiac/*prevention & controlen
dc.subjectClinical Trials as Topicen
dc.subjectCoronary Artery Disease/*epidemiologyen
dc.subjectDeath, Sudden, Cardiac/*prevention & controlen
dc.subject*Defibrillators, Implantableen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectProspective Studiesen
dc.subjectRandomized Controlled Trials as Topicen
dc.subjectRisk Factorsen
dc.subjectTreatment Outcomeen
dc.titleProphylactic implantable cardioverter defibrillator therapy in high-risk patients with coronary artery diseaseen
heal.abstractDespite substantial progress in the management of ischemic heart disease and congestive heart failure, long-term mortality rates as a result of sudden cardiac death in such patients remain significant. Risk stratification that uses a combination of several predictors of clinical outcome has improved our ability to identify persons at high risk for future arrhythmic events. beta-Blockers and amiodarone are effective in primary prevention of sudden death in selected populations. In view of the impressive reduction in sudden death rates by implantable cardioverter defibrillators (ICDs) in patients with a history of cardiac arrest, prophylactic implantation may also be beneficial. The best way to treat these patients is not known. Three ongoing controlled clinical trials have been designed for drugs, ICDs, or both and will provide answers about whether prophylactic antiarrhythmic intervention with ICDs improves survival and whether device therapy is superior to pharmacologic treatment. Brief reports on these clinical trials are discussed in this review.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/7909188-
heal.journalNameAm Heart Jen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1994-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Φόρτωση...
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή: